drugset / Trial / NCT05157360

HAT for the Treatment of Sepsis Associated With NASTI

NCT05157360

Phase 1/2 Terminated 10 enrolled Ascension Health University of Kansas · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

Evaluate the impact of HAT therapy versus placebo in the treatment of patients with an acute NSTI and sepsis.

Timeline

Start
2021-09-10
Primary completion
2023-05-16
Completion
2023-05-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrocortisone Other / unclassified 50 mg
Subject Thiamine Other / unclassified 200 mg
Subject Vitamin C Other / unclassified 1.5 g